[HTML][HTML] Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

L Han, C Jiang - Acta Pharmaceutica Sinica B, 2021 - Elsevier
Blood–brain barrier (BBB) strictly controls matter exchange between blood and brain, and
severely limits brain penetration of systemically administered drugs, resulting in ineffective …

Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers

null Wahajuddin, S Arora - International journal of nanomedicine, 2012 - Taylor & Francis
A targeted drug delivery system is the need of the hour. Guiding magnetic iron oxide
nanoparticles with the help of an external magnetic field to its target is the principle behind …

In vivo biodistribution and clearance of magnetic iron oxide nanoparticles for medical applications

J Nowak-Jary, B Machnicka - International Journal of …, 2023 - Taylor & Francis
Magnetic iron oxide nanoparticles (magnetite and maghemite) are intensively studied due to
their broad potential applications in medical and biological sciences. Their unique …

Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous …

JS Weinstein, CG Varallyay, E Dosa… - Journal of Cerebral …, 2010 - journals.sagepub.com
Superparamagnetic iron oxide nanoparticles have diverse diagnostic and potential
therapeutic applications in the central nervous system (CNS). They are useful as magnetic …

Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier

O Veiseh, C Sun, C Fang, N Bhattarai, J Gunn, F Kievit… - Cancer research, 2009 - AACR
Nanoparticle-based platforms have drawn considerable attention for their potential effect on
oncology and other biomedical fields. However, their in vivo application is challenged by …

Advances in nanomedicines for diagnosis of central nervous system disorders

X Zhang, J Zhou, Z Gu, H Zhang, Q Gong, K Luo - Biomaterials, 2021 - Elsevier
In spite of a great improvement in medical health services and an increase in lifespan, we
have witnessed a skyrocket increase in the incidence of central nervous system (CNS) …

Focal cortical dysplasia type II: biological features and clinical perspectives

SM Sisodiya, S Fauser, JH Cross, M Thom - The Lancet Neurology, 2009 - thelancet.com
Focal cortical dysplasia (FCD) type II is an important cause of drug-resistant epilepsy.
Clinical presentation is variable, and depends on age of onset of seizures and the location …

ROS/electro dual-reactive nanogel for targeting epileptic foci to remodel aberrant circuits and inflammatory microenvironment

Z Zhou, K Li, Y Guo, P Liu, Q Chen, H Fan, T Sun… - ACS …, 2023 - ACS Publications
Medicinal treatment against epilepsy is faced with intractable problems, especially
epileptogenesis that cannot be blocked by clinical antiepileptic drugs (AEDs) during the …

The current status of neuroimaging for epilepsy

J Duncan - Current opinion in neurology, 2009 - journals.lww.com
Summary MRI at 3T with FLAIR and multiple channel coils identifies and clarifies relevant
abnormalities in 20% of patients with previously unremarkable scans. Voxel-based analysis …

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

M Matias, AO Santos, S Silvestre, G Alves - Pharmaceutics, 2023 - mdpi.com
Epilepsy is a chronic and complex condition and is one of the most common neurological
diseases, affecting about 50 million people worldwide. Pharmacological therapy has been …